Health Technology Assessment in Pharma: A Review of Major Decisions

May 2020| PHM228A| BCC Publishing

Report Highlights

The goal of this study is to provide information on the global health technology approval process in North America, Europe and the Asia-Pacific region. The study emphasizes the role of HTA and its function and technology process in the pharmaceutical industry. The report also elaborates on recent HTA approvals and their significance on pricing and reimbursement.

Report Includes

  • 45 tables
  • A detailed outlook on the HTA process and its approvals in major pharma industries
  • Insights into the recent HTA submissions to HTA agencies by top pharmaceutical manufacturers
  • Discussion on how HTA helps in the development of safe, and effective health policies, thereby benefitting both patient and health care providers
  • Information about the medical, social, economic and ethical issues related to the use of a health technology
  • Company profiles of market-leading players, including Janssen Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Co., and Hofmann-La Roche Inc.

Report Scope

The current report provides details about HTA processes in countries such as U.S., Canada and U.K. This report highlights information and insights on the molecules which were recently approved in terms of regulatory and reimbursement decisions. The report includes policies, country-specific HTA activities, drug overviews, mechanisms of action, disease backgrounds, clinical evidence on safety and efficacy, regulatory scenarios, and HTA evaluation details.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesPrice Member Price
Full Report: Health Technology Assessment in Pharma: A Review of Major Decisions82 $2,750 Free
Chapter- 1: Introduction3Free
Chapter- 2: Introduction to Health Technology Assessment4$250Free
Chapter- 3: Pharmaceutical Industry’s Perspective on HTA2$67Free
Chapter- 4: Overview of Global HTA Organizations39$1,308Free
Chapter- 5: Daratumumab (Darzalex)7$235Free
Chapter- 6: Tildrakizumab (Ilumya)5$168Free
Chapter- 7: Durvalumab (Imfinzi)7$235Free
Chapter- 8: Abemaciclib (Verzenio)7$235Free
Chapter- 9: Ocrelizumab (Ocrevus)7$235Free
Chapter- 10: Conclusion1$34Free
Health Technology Assessment in Pharma: A Review of Major Decisions

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries